Cargando…
Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study)
BACKGROUND: Anti‐PD‐1‐based immunotherapy is considered a preferred first‐line treatment for advanced BRAF V600‐mutant melanoma. However, a recent international multi‐center study suggested that the efficacy of immunotherapy is poorer in Asian patients in the non‐acral cutaneous subtype. We hypothes...
Autores principales: | Namikawa, Kenjiro, Ito, Takamichi, Yoshikawa, Shusuke, Yoshino, Koji, Kiniwa, Yukiko, Ohe, Shuichi, Isei, Taiki, Takenouchi, Tatsuya, Kato, Hiroshi, Mizuhashi, Satoru, Fukushima, Satoshi, Yamamoto, Yosuke, Inozume, Takashi, Fujisawa, Yasuhiro, Yamasaki, Osamu, Nakamura, Yasuhiro, Asai, Jun, Maekawa, Takeo, Funakoshi, Takeru, Matsushita, Shigeto, Nakano, Eiji, Oashi, Kohei, Kato, Junji, Uhara, Hisashi, Miyagawa, Takuya, Uchi, Hiroshi, Hatta, Naohito, Tsutsui, Keita, Maeda, Taku, Matsuya, Taisuke, Yanagisawa, Hiroto, Muto, Ikko, Okumura, Mao, Ogata, Dai, Yamazaki, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524053/ https://www.ncbi.nlm.nih.gov/pubmed/37584204 http://dx.doi.org/10.1002/cam4.6438 |
Ejemplares similares
-
Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients
por: Mori, Tatsuhiko, et al.
Publicado: (2023) -
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
por: Yokota, Kenji, et al.
Publicado: (2019) -
Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020) -
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2017) -
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
por: Nakamura, Y., et al.
Publicado: (2021)